The models incorporate estimates of age-specific breast cancer incidence and estrogen receptor (ER)/human epidermal growth factor receptor 2 (HER2) subtype-specific survival trends in the absence of screening or treatment and then incorporate information on how screening and molecular subtype-specific treatment patterns affect the underlying trends. This evidence concerns the gene ERBB2 and breast carcinoma.